Hetrombopag(SHR8735,(Z)-5-(2-hydroxy-3-(2-(3-methyl-5-oxo-1-(5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrazol-4(5H)-ylidene)hydrazinyl)phenyl)furan-2-carboxylic acid), the analog of eltrombopag, was developed by Jiangsu Hengrui pharmaceutical company limited as a novel patented thrombopoietin receptor agonist to treat idiopathic thrombocytopenia (Tang et al. 2009). This evidence concerns the gene MPL and autoimmune thrombocytopenic purpura.